ReviewCurrent neuropharmacology2021
Current and Emerging Treatments for Methamphetamine Use Disorder.
Review in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07121296 (Screen, Treat and Retain People With Primary Meth Use Disorder at MMT Clinics), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screen, Treat and Retain People With Primary Meth Use Disorder at MMT Clinics
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Effect of N-acetylcysteine on craving in substance use disorders (SUD): a meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2024Pooled it
- Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial.The Journal of clinical psychiatry · 2025Trial
- Mitragynine reduces methamphetamine self-administration in rats without disrupting food-maintained responding.Psychopharmacology · 2026Article
- Methamphetamine Use and HIV Risk Behaviors in a Cohort of Homeless-Experienced Adults Who Use Drugs.AIDS and behavior · 2026Article
- Morphine and methamphetamine trigger divergent post-transcriptional neuroimmune landscapes in the dorsal striatum.bioRxiv : the preprint server for biology · 2026Article
- Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization.AIDS care · 2026Article
- Psychosocial, Behavioral, and HIV-Related Health Among Men Living with HIV Who Have a History of Incarceration.AIDS and behavior · 2026Article
- Specific Glutamatergic Projection to Claustrum for Regulating Methamphetamine Abstinence Anxiety-Like Behaviors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Article
- Naltrexone blocks the sleep-disrupting effects of methamphetamine in male rhesus monkeys.Drug and alcohol dependence · 2025Article
- Effects of methamphetamine-induced sleep disruption on intradimensional/extradimensional attentional set-shifting in adult rhesus monkeys.The Journal of pharmacology and experimental therapeutics · 2025Article
- Evaluating markers for methamphetamine use in electronic health records.Drug and alcohol dependence · 2025Article
- Understanding African American/Black and Latine young and emerging adults living with HIV: a sequential explanatory mixed methods study focused on self-regulatory resources.International journal for equity in health · 2025Article
- Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.Biomolecules · 2025Review
- Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotheraBMJ open · 2025Article
- Single-Cell RNA-Seq Uncovers Robust Glial Cell Transcriptional Changes in Methamphetamine-Administered Mice.International journal of molecular sciences · 2025Article
- A Mechanistic Review on Toxicity Effects of Methamphetamine.International journal of medical sciences · 2025Review
- Environmental enrichment as a therapeutic strategy against methamphetamine induces depressive behaviors in mice.PloS one · 2025Article
- The role of brain creatine in behavioral health conditions.Frontiers in psychiatry · 2025Review
- Therapeutic targeting of neuroinflammation in methamphetamine use disorder.Future medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Almost two decades have passed since the last methamphetamine (METH) abuse epidemic. In recent years, METH abuse in the United States has been rapidly increasing and is currently one of the leading causes of death in our country. Available statistical data indicates reemergence of METH popularity and suggest an impending third epidemic of METH abuse. Alarmingly, there is no FDA-approved medication for METH use disorder (MUD). This disorder is currently treated with behavioral therapies; however, these therapies have limitations and would benefit from the addition of a MUD pharmacotherapy. Unfortunately, clinical trials have not yet found consistently effective pharmacotherapy for MUD. This review outlines the history of METH use, provides information on current prevalence of METH abuse and MUD, describes medications that have been in clinical trials for MUD, and addresses current as well as potential new treatments for MUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.